The Omega Diagnostics (ODX) share price is falling. Should I buy now?

The Omega Diagnostics (ODX) share price recently started falling. Is this a buying opportunity? Zaven Boyrazian investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Omega Diagnostics (LSE:ODX) share price has been moving like a rollercoaster recently. After surging by more than 300% in 2020, the stock has continued to climb. But recently, it’s started slumping. What’s going on? And is this a buying opportunity for my portfolio? Let’s take a look.

The volatile ODX share price

I’ve previously explored Omega Diagnostics. But as a quick reminder, the company offers products to detect food intolerances, allergies, and viral infections. At the start of the pandemic, the management team decided to utilise the firm’s technology to quickly develop antibody tests for Covid-19.

In retrospect, this pivot proved to be a wise decision. Why? Because it subsequently led to a signed contract with the UK Department of Health and Social Care that could be worth up to £374m.

Under the agreement, Omega Diagnostics will be using its manufacturing capacity to produce up to two million lateral flow tests per week by the end of this month. And based on its most recent update, it’s on track to achieve this goal.

Given that the firm’s pre-pandemic revenue was around £9.8m, this contract is undoubtedly a major opportunity. So I’m not surprised by the explosive growth of the ODX share price last year. But there seems to be some growing uncertainty among investors about the company’s future potential, those worries causing the recent decline.

Looking to the future

As promising as the most recent update is, the company still has a vast array of challenges that lie ahead. While the Covid-19 contract may be game-changing, there is no guarantee that Omega Diagnostics will receive the full amount. After all, with the number of vaccinations increasing relatively quickly, the demand for these tests is falling.

Even if Omega Diagnostics can extract the maximum value from this contract, the source of revenue is ultimately unsustainable. So the question is, how will it generate future sales? The firm does have an existing portfolio of other products that have been generating income for many years. But not on the same scale.

The surge in cash flow from this contract will likely provide the business with additional capital to further expand its portfolio of offerings. However, the medical industry is one of the most regulated in the world. And therefore, bringing new products to market may take a long time. Suppose it cannot maintain the level of sales that investors are now expecting. In that case, I think it’s likely that the ODX share price will continue its downward trajectory, over the short term anyway.

The Omega Diagnostics ODX share price has its risks

The bottom line

Omega Diagnostics looks like a healthy and robust business in my eyes. But even after the recent tumble in the ODX share price, the valuation still seems propped up by investor expectations that may not come to pass. And so, for now, I’m keeping it on my watch list.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Omega Diagnostics. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »